Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine (Experimental) Clear all
Terminated Not applicable Interventional

Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids

NCT06569667
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
PRC supported text + AI driven SDH-enhanced text, AI driven SDH-enhanced text only, Treatment as Usual (TAU)
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 99 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Not applicable Interventional Results available

Fostering MAT Use in Justice Populations

NCT04363320
View directory record Official record
Conditions
Opioid-use Disorder, Recidivism
Interventions
NIATx Coaching, ECHO
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

NCT01738503
View directory record Official record
Conditions
Opioid Related Disorder
Interventions
RBP-6000, Subutex
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 4, 2026, 4:46 PM EDT
Terminated Phase 4 Interventional Results available

Buprenorphine as a Treatment in Opiate Dependent Pain Patients

NCT00552578
View directory record Official record
Conditions
Opiate Addiction, Refractory Pain
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Oct 4, 2026, 4:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department

NCT07430345
View directory record Official record
Conditions
Fracture
Interventions
Buprenorphine 0.15 MG, Hydromorphone 0.25 mg IV
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

NCT01366001
View directory record Official record
Conditions
Cocaine Abuse
Interventions
ALKS 33-BUP, ALKS 33, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects

NCT01675167
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Effective Treatment for Prescription Opioid Abuse

NCT00719095
View directory record Official record
Conditions
Prescription Opioid Dependence
Interventions
buprenorphine taper followed by naltrexone maintenance, Behavioral therapy
Drug · Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 4, 2026, 4:46 PM EDT
Terminated Phase 4 Interventional Results available

Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain

NCT01875848
View directory record Official record
Conditions
Pain
Interventions
buprenorphine/naloxone, opioid dose escalation
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 4, 2026, 4:46 PM EDT
Enrolling by invitation Phase 4 Interventional

Houston Emergency Opioid Engagement System

NCT03396276
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Suboxone, Brief counseling in the ED, Referral to outpatient treatment, Follow-up coaching
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

NCT00000318
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients

NCT00879996
View directory record Official record
Conditions
Opiate Addiction
Interventions
Methadone, Buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 4, 2026, 4:46 PM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Prescription Opioid Addiction Treatment Study (POATS)

NCT00316277
View directory record Official record
Conditions
Opiate Dependence, Substance-related Disorders, Opioid-related Disorders
Interventions
Standard Medical Management (SMM) of Prescription Opiate Abuse, Enhanced Medical Management (EMM) of Prescription Opiate Abuse
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Lawrenceburg, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 4, 2026, 4:46 PM EDT
Withdrawn Phase 2 Interventional

Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain

NCT02276989
View directory record Official record
Conditions
Compliance, Chronic Pain
Interventions
acetazolamide, Quinine, Riboflavin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Not applicable Interventional Results available

Emergency Department Longitudinal Integrated Care

NCT03699085
View directory record Official record
Conditions
Opioid-use Disorder, Emergency Department
Interventions
ED-LINC
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 4, 2026, 4:46 PM EDT
Recruiting Phase 4 Interventional

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

NCT04375033
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
25
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain

NCT02372591
View directory record Official record
Conditions
Opioid-Related Disorders, Chronic Pain
Interventions
Buprenorphine, Hydromorphone, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

NCT02537574
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Oceanside, California • Orange, California • Lauderhill, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans

NCT02891798
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone), Bupivacaine Only (control arm)
Drug
Lead sponsor
Brian Williams
Federal
Eligibility
18 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 4, 2026, 4:46 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

NCT00312221
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine, oxycodone immediate-release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • Chula Vista, California • Roseville, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Health Intervention to Support Opioid Use Disorder Treatment

NCT03842384
View directory record Official record
Conditions
Opioid Use Disorder, Treatment Adherence
Interventions
iENDURE
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 4, 2026, 4:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 4, 2026, 4:46 PM EDT